Last updated: April 25, 2026
EPIPEN is a brand name for an epinephrine auto-injector. Supply is handled through a branded supply chain (manufacturer and distributor) and a component supply chain (device, pen mechanics, needle/sterile packaging, and drug substance or finished-dose filling, depending on the product’s manufacturing model). EPIPEN is typically sourced through a small set of upstream makers who supply the finalized product to national distributors.
Which companies manufacture EPIPEN auto-injector products?
A complete, definitive supplier list depends on country-specific brand registration, label, and local marketing authorizations. EPIPEN is marketed in multiple jurisdictions, and the manufacturing and distribution role can change by territory and regulatory lifecycle.
Below is the procurement-relevant supplier segmentation you should use for due diligence:
1) Marketing authorization holder (MAH) and branded distributor
This entity controls label supply and is the first stop for “who supplies product into the market” for each country.
- Tracks: “Manufactured by,” “Distributed by,” and local site names on the package insert / product leaflet
- Often the entity that executes supply agreements with local wholesalers, hospitals, and government tenders
2) Drug product manufacturer (finished dose filling + device assembly)
This is the entity that produces the finished epinephrine auto-injector (drug fill, device assembly, and packaging).
- Tracks: batch release site and “Manufactured at” addresses in the package insert
- Commonly uses contract manufacturing (drug fill and device assembly can be in different plants)
3) Device supplier (pen mechanics, springs, actuator, needle housing)
Auto-injectors rely on a device supplier base that can include:
- Pen mechanism and housing
- Needle and needle shield components
- Sterile packaging materials and primary container formats
4) Drug substance and/or drug product bulk supply
Depending on manufacturing model:
- Drug substance may be supplied to a fill/finish site
- Finished-dose filling may be performed at a contract manufacturer or internal site
What is the supplier map for EPIPEN across the supply chain?
Use this decision table to separate “supplier” into contract categories that matter for procurement and IP diligence:
| Supply chain layer |
What it supplies |
Supplier evidence to pull from EPIPEN documents |
Procurement outcome |
| MAH / distributor |
Market-ready branded product |
“Distributed by” / “Marketing authorization holder” fields |
Determines who signs local supply and tenders |
| Finished dose manufacturer |
Filled, assembled, packaged auto-injector |
“Manufactured at” and batch release addresses |
Determines quality system owner for release testing |
| Device maker / component OEM |
Auto-injector mechanical parts |
Engineering specs and device part traceability; packaging/labeling statements |
Identifies actuator/needle OEM risk and lead times |
| Fill/finish partner |
Epinephrine fill into device |
Site statements in the leaflet and manufacturing sections |
Confirms whether supply is constrained by fill capacity |
How to identify EPIPEN suppliers in practice (document-first method)
EPIPEN supplier identification should be grounded in label and regulatory documents that name manufacturing and distribution parties. The relevant fields are consistent across EU and UK-style product leaflets and patient information leaflets:
Fields that normally name suppliers
- “Manufactured by” (finished dose and assembly site)
- “Distributed by” (local distributor)
- “Marketing authorization holder”
- “Batch released by” or equivalent quality release language
- Address blocks tied to the above roles
Where to find those fields
- EPIPEN package insert / patient information leaflet for each target country
- EMA/UK regulator product pages for the brand and strength
- National medicines agency product dossiers where public label text is accessible
Key country-based takeaway: EPIPEN suppliers change by territory
Even when the same brand name is used, the supplier and distributor can differ because:
- Product authorization is national (or regional) and label text must match local approvals
- Companies often use different contract manufacturers and logistics partners per market
What’s the contracting reality for epinephrine auto-injectors like EPIPEN?
Most auto-injector supply chains operate as multi-site systems:
- Drug fill/finish is capacity constrained and can be geographically distinct from
- Device assembly and packaging, which is frequently run at a specialized device facility
- Component OEMs (needle/actuator) can have separate long-lead ordering
That structure matters for supplier selection because lead times and continuity risk sit with the longest constrained node, which is often device-related or sterile packaging related.
Supplier due diligence checklist for EPIPEN procurement
For each EPIPEN strength and market:
- Capture the named “Manufactured by” site (finished dose and assembly)
- Capture the named “Distributed by” or MAH in the local leaflet
- Verify whether drug fill and device assembly happen at the same site
- Confirm sterility and primary packaging statements match the named site capability
- Validate batch traceability by the labeled manufacturing/packaging addresses
Key Takeaways
- EPIPEN supplier identification is territory-specific because label and regulatory packaging assign different manufacturing and distribution parties by country.
- Treat “suppliers” as four contract layers: MAH/distributor, finished-dose manufacturer, device/component OEM, and fill/finish partner.
- The fastest, most reliable way to determine who supplies EPIPEN in a given market is to extract the manufactured by / distributed by / MAH addresses from the EPIPEN package insert for that exact strength and country.
FAQs
-
Is the EPIPEN manufacturer the same as the distributor?
Not always. The leaflet typically names both roles, and they can be different entities.
-
Do EPIPEN suppliers change when you switch countries?
Yes. Brand approval and labeling are market-specific, which often leads to different manufacturing/distribution assignments.
-
How do you identify the true finished-dose supplier for EPIPEN?
Use the EPIPEN package insert fields that list “Manufactured by” and the address tied to batch release or manufacturing.
-
What parts of an auto-injector supply chain are most likely to drive lead times?
Needle/sterile packaging and device assembly components often carry the longest lead times and capacity constraints.
-
What documents should be used to confirm EPIPEN supplier relationships?
The EPIPEN package insert/patient leaflet for the target market and the regulator product listing that mirrors the label text.
References
[1] European Medicines Agency. (n.d.). Product information and EPAR/PL data for epinephrine auto-injectors (access via EPAR/medicinal product pages). EMA. https://www.ema.europa.eu/
[2] UK Medicines and Healthcare products Regulatory Agency. (n.d.). Drug product information and patient information leaflets for authorized medicines. MHRA. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
[3] U.S. Food and Drug Administration. (n.d.). Drug safety communications and product label repository (for comparator context on auto-injector labeling practices). FDA. https://www.fda.gov/drugs
